Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Jul 21, 2017
CAMBRIDGE, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company's U.S. Patent No. 7,575,886, covering methods for the manufacturing of generic LOVENOX® (Enoxaparin Sod...
Jul 19, 2017
CAMBRIDGE, Mass., July 19, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2017 before the U.S. financial markets open on Wednesday, August 2, 2017.    M...
Jun 7, 2017
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory submissions for marketing approval for M923, its ...
Jun 1, 2017
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Senior Vice President, Development. "Santiago's deep under...
May 10, 2017
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences. Bank of America Merrill Lynch 2017 Health Care Conference We...
May 2, 2017
--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the first quarter with a strong cash position of $434 million--CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter end...
Apr 26, 2017
CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation is scheduled for Wednesday, May 3rd at 10:00...
Apr 18, 2017
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.    Manag...
Feb 28, 2017
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10...
Feb 21, 2017
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016. For the fourth quarter of 2016, the Company reported total revenues of $34.2 million, including $15.8 million in product revenues from Sandoz's sales of ...
1
...
NextLast
= add release to Briefcase